Jan Schleicher

Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients With Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group

Hans‐Joachim Schmoll, Christian Kollmannsberger, Bernd Metzner et al. · Journal of Clinical Oncology · 2003 · 160 citations

Medicine, Oncology, Chemotherapy +15

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Single Versus Sequential High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: A Prospective Randomized Multicenter Trial of the German Testicular Cancer Study Group

Anja Lorch, Christian Kollmannsberger, J. T. Hartmann et al. · Journal of Clinical Oncology · 2007 · 146 citations · Full text

Medicine, Oncology, Cancer Control +15

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with <i>NPM1</i>-mutated AML: results from the AMLSG 09-09 trial

Silke Kapp‐Schwoerer, Daniela Weber, Andrea Corbacioglu et al. · Blood · 2020 · 119 citations · Full text

Medicine, Oncology, Pharmacology +10

Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study

Richard F. Schlenk, Peter Paschka, Julia Krzykalla et al. · Journal of Clinical Oncology · 2019 · 112 citations · Full text

Medicine, Hematology, Oncology +15